A Form 4 filed with the SEC on September 4, 2026 discloses that Joseph A. Tyndall, a director of Axogen, Inc. (NASDAQ:AXGN), sold 3,500 shares of common stock on September 2, 2026 under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Shares sold: Tyndall disposed of 3,500 shares of Axogen common stock on September 2, 2026.
- Weighted average price: The reported sale price was a weighted average of $49.697 per share.
- Price range: Individual transactions occurred at prices ranging from $48.01 to $51.46 per share.
- Shares retained: Following the sale, Tyndall beneficially owned 10,650 shares directly.
- 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2026.
- Role: Tyndall is identified in the filing as a director of Axogen, Inc.
Axogen Director Executes Planned Share Sale Under 10b5-1 Program
According to the Form 4 filed September 4, 2026, Joseph A. Tyndall sold 3,500 shares of Axogen, Inc. common stock on September 2, 2026. The filing identifies Tyndall as a director of the company, with an address listed as c/o Axogen, Inc., 13631 Progress Blvd., Suite 400, Alachua, Florida 32615. The transaction was marked with transaction code "S," indicating a sale, and is reported as a direct ownership disposition.
The filing notes that the reported price of $49.697 represents a weighted average sale price, as the shares were sold across multiple transactions at prices ranging from $48.01 to $51.46 per share. According to the filing, "The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."
The filing discloses that the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2026, as indicated by the checked box on the form. Following the reported transaction, Tyndall's direct beneficial ownership of Axogen common stock stands at 10,650 shares, according to the filing. No derivative securities transactions were reported in this filing. The form was signed by Marc Began as attorney-in-fact for Joseph A. Tyndall.
What Was Disclosed
This Form 4 reports the sale of 3,500 Axogen common shares by director Joseph A. Tyndall on September 2, 2026, at a weighted average price of $49.697 per share under a pre-established 10b5-1 plan, leaving him with 10,650 shares directly held.


Please wait processing your request...